Muraki Michiro, Hirota Kiyonori
Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki, 305-8566, Japan.
BMC Biotechnol. 2017 Jul 3;17(1):56. doi: 10.1186/s12896-017-0381-2.
Fas ligand plays a key role in the human immune system as a major cell death inducing protein. The extracellular domain of human Fas ligand (hFasLECD) triggers apoptosis of malignant cells, and therefore is expected to have substantial potentials in medical biotechnology. However, the current application of this protein to clinical medicine is hampered by a shortage of the benefits relative to the drawbacks including the side-effects in systemic administration. Effective procedures for the engineering of the protein by attaching useful additional functions are required to overcome the problem.
A procedure for the site-specific chemical conjugation of hFasLECD with a fluorochrome and functional proteins was devised using an inverse-electron-demand Diels-Alder reaction between trans-cyclooctene group and methyltetrazine group. The conjugations in the present study were attained by using much less molar excess amounts of the compounds to be attached as compared with the conventional chemical modification reactions using maleimide derivatives in the previous study. The isolated conjugates of hFasLECD with sulfo-Cy3, avidin and rabbit IgG Fab' domain presented the functional and the structural integrities of the attached molecules without impairing the specific binding activity toward human Fas receptor extracellular domain.
The present study provided a new fundamental strategy for the production of the engineered hFasLECDs with additional beneficial functions, which will lead to the developments of the improved diagnostic systems and the effective treatment methods of serious diseases by using this protein as a component of novel molecular tools.
Fas配体作为一种主要的细胞死亡诱导蛋白,在人类免疫系统中发挥着关键作用。人Fas配体的细胞外结构域(hFasLECD)可触发恶性细胞的凋亡,因此在医学生物技术领域具有巨大潜力。然而,目前该蛋白在临床医学中的应用受到诸多限制,相对于包括全身给药副作用在内的缺点,其益处不足。需要有效的方法对该蛋白进行工程改造,赋予其有用的附加功能以解决这一问题。
利用反电子需求的狄尔斯-阿尔德反应,即反式环辛烯基团与甲基四嗪基团之间的反应,设计了一种将hFasLECD与荧光染料及功能蛋白进行位点特异性化学偶联的方法。与先前研究中使用马来酰亚胺衍生物的传统化学修饰反应相比,本研究中偶联反应所使用的待连接化合物的摩尔过量量要少得多。分离得到的hFasLECD与磺基-Cy3、抗生物素蛋白及兔IgG Fab'结构域的偶联物,在不损害其对人Fas受体细胞外结构域特异性结合活性的情况下,呈现出所连接分子的功能和结构完整性。
本研究为生产具有附加有益功能的工程化hFasLECD提供了一种新的基本策略,这将推动利用该蛋白作为新型分子工具的组成部分,开发改进的诊断系统和严重疾病的有效治疗方法。